Business Context and Reporting Period
MacroGenics, Inc. (MGNX) filed a Form 8-K on July 7, 2026, reporting events occurring on June 30, 2026. The filing details the completion of a strategic asset disposition involving the company's Contract Development and Manufacturing Organization (CDMO) business.
Key Financial Metrics
- Transaction Proceeds: The company received $122.5 million in cash at closing, before transaction fees and expenses.
- Adjustments: The final consideration is subject to customary post-closing adjustments.
- Assets Disposed: GMP manufacturing operations at 9704 Medical Center Drive, Rockville, MD, and warehouse operations at 4735 Arcadia Drive, Frederick, MD.
- Exclusions: Research and related assets and operations were excluded from the sale.
- Financial Statements: Unaudited pro forma consolidated financial information is provided in Exhibit 99.2 for the year ended December 31, 2025, and the three months ended March 31, 2026.
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period, as this is a current report focused on a specific transaction rather than a periodic financial statement.
Material Changes
Effective June 30, 2026, MacroGenics completed the sale of its CDMO Operations to Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC. The Purchaser assumed responsibility for the CDMO Operations, marking a significant shift in the company's operational footprint and asset base.
Guidance, Outlook, and Risks
The filing references a press release issued on July 2, 2026, regarding the closing. While the transaction removes the CDMO business, the filing does not contain explicit forward-looking guidance, management commentary on future strategy, or specific risk factors related to the transaction beyond the standard incorporation of the Purchase Agreement by reference. The pro forma financial information allows investors to assess the historical impact of the disposition.
Investor Verification Checklist
- Verify the final transaction amount after customary post-closing adjustments.
- Review the unaudited pro forma financial statements (Exhibit 99.2) to understand the impact on the balance sheet and operations.
- Confirm the specific transaction fees and expenses deducted from the $122.5 million gross proceeds.
- Examine the full Asset Purchase Agreement (filed May 12, 2026) for any retained liabilities or contingent obligations.